Investigating the Association of Shock Index & Hemoglobin Variation With

Status Completed

Clinical Trial Summary

Postpartum hemorrhage (PPH) is a leading cause of maternal mortality and morbidity, and is most commonly caused by poor uterine tone after delivery of the baby and placenta. Currently, a lack of early identification of PPH also results in delayed treatment, with an increase in morbidity. The investigators propose that 2 non-invasive methods may provide monitoring for early and accurate detection of PPH. These methods include shock index (SI) and continuous hemoglobin (Hb) monitoring. SI is defined as heart rate divided by systolic blood pressure, and can be used as a marker to predict the severity of hypovolemic shock. Continuous Hb monitoring can now be done using a non-invasive probe that is placed on the patient's finger. It provides real-time Hb values, rather than having to draw blood and wait for a lab test.

The investigators hypothesize that SI will have a stronger association with postpartum blood loss than Hb variation.

Clinical Trial Description

The investigators believe that trends in patient-specific SI combined with continuous SpHb monitoring, will be useful to identify PPH and the immediate need for pharmacotherapy, as well as the need for transfusion in obstetric patients undergoing vaginal deliveries. The investigators expect shock index to increase and SpHb levels to decrease with increasing blood loss after delivery. The compensatory hemodynamic response may start early, however, Hb variation may be delayed unless the patient is transfused with crystalloids. Also autotransfusion after delivery may influence these measures. It is unknown which one of the two indicators, SI or SpHb, has a stronger association with blood loss after vaginal delivery.

It is already established that both SI and SpHb are independent, clinically useful markers indicating significant blood loss in elective cesarean delivery and trauma. This study would assess their utility in the recognition and management of obstetric hemorrhage following normal vaginal delivery, where early recognition and resuscitation reduces the risk of progressing to hemorrhagic shock, disseminated intravascular coagulation and death. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03432767
Study type	Observational
Source	Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Contact
Status	Completed
Phase
Start date	February 16, 2016
Completion date	January 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03434444` - In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol	N/A
Terminated	`NCT01980173` - Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care	N/A
Not yet recruiting	`NCT06033170` - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage	N/A
Completed	`NCT02163616` - Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study	Phase 3
Not yet recruiting	`NCT02319707` - Management of the Third Stage of Labor	Phase 3
Recruiting	`NCT01600612` - Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial	N/A
Completed	`NCT02079558` - Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section	Phase 2
Withdrawn	`NCT01108302` - Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India	N/A
Completed	`NCT00097123` - RCT of Misoprostol for Postpartum Hemorrhage in India	N/A
Completed	`NCT02883673` - Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage	N/A
Completed	`NCT02542813` - Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers	Phase 1
Completed	`NCT04201665` - EMG for Uterotonic Efficiency Estimation	N/A
Terminated	`NCT03246919` - Ideal Time of Oxytocin Infusion During Cesarean Section	Phase 4
Not yet recruiting	`NCT05501106` - Reducing Postpartum Hemorrhage After Vaginal Delivery	N/A
Completed	`NCT05429580` - Prophylactic Tranexamic Acid Use After Vaginal Delivery	N/A
Terminated	`NCT03064152` - Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery	N/A
Recruiting	`NCT05382403` - Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage	N/A
Not yet recruiting	`NCT02853552` - Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding	Phase 4
Completed	`NCT02805426` - Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage	Phase 4
Completed	`NCT03344302` - Oxytocin Administration During Cesarean Section	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Investigating the Association of Shock Index and Hemoglobin Variation With Postpartum Hemorrhage After Vaginal Deliveries

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms